Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTYP01 Tablets in Acute Ischemic Stroke
CTR20230707Phase 3Completed
- Sponsor
- Suzhou Aozong Biotechnology
- Start
- Mar 2023
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of FAB122 in ischemic stroke, sponsored by Suzhou Aozong Biotechnology. Started Mar 2023; status: completed.
02
Drugs
FAB122
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20230707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230707.